MBD3L5

Across TCGA pan-cancer cohorts, MBD3L5 RNA is linked to patient survival in 6 of 34 cancer types, making it the most broadly survival-associated MBD3L5 data layer.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher MBD3L5 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MBD3L5 expression acts as an unfavorable survival marker.

CESC, THCA, and SARC are the cancer types where MBD3L5 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Tertile	III,IV	0.091	0.755	<.001	72	view →
THCA	DFS	Tertile	All	0.070	0.896	<.001	54	view →
SARC	OS	Tertile	All	0.127	0.522	<.001	51	view →
UCS	DFS	Tertile	All	0.154	0.530	.013	36	view →
HNSC	DFS	Tertile	IV	0.176	0.588	.001	21	view →
SKCM	DFS	Tertile	III,IV	0.044	0.597	<.001	9	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MBD3L5–CESC (OS)

Open the CESC breakdown →